Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Carlos Manuel Buesa Arjol | Co-Founder, Chairman, CEO & President | 456k | -- | -- |
| Mr. Enric Rello Condomines | COO & CFO | -- | -- | -- |
| Mr. Jordi Xaus Pey | Scientific Director | -- | -- | -- |
| Mr. Xavier Perpinya Ribera | Head of Internal Audit & Compliance | -- | -- | -- |
| Mr. Augusto Pinel Rubio | Secretary | -- | -- | -- |
| Mr. Emili Torrell Cortada | Director of Business Development | -- | -- | -- |
| Ms. Neus Virgili Bernado | Director of Industrial Property | -- | -- | -- |
| Dr. Michael Thomas Ropacki Ph.D. | Medical Director of SNC | -- | -- | -- |
| Ms. Sonia Paloma Gutierrez Bezon | Director of Clinical Operations | -- | -- | -- |
Oryzon Genomics S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 46
Description
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Corporate Governance
Upcoming Events
February 24, 2025 at 10:59 AM UTC - February 28, 2025 at 12:00 PM UTC
Oryzon Genomics S.A. Earnings Date
Recent Events
Recent Events Information Not Available